1.Efficacy of Intravitreal Triamcinolone Acetonide for Eyes with Postvitrectomy Diabetic Vitreous Hemorrhage.
Sun Young LEE ; Hee Gyung LEE ; Hyewon CHUNG ; Young Hee YOON ; June Gone KIM
Korean Journal of Ophthalmology 2007;21(4):208-212
PURPOSE: To evaluate the efficacy of intravitreal triamcinolone acetonide (IVT) for the management of postvitrectomy diabetic vitreous hemorrhage. METHODS: The authors conducted a retrospective study of patients with postvitrectomy diabetic vitreous hemorrhage who were administered 4 mg (0.1 cc) of triamcinolone acetonide ophthalmic suspension. Ocular history, adverse events, BCVA, intraocular pressure, external eye examination, slit-lamp biomicroscopy, fundus examination, B-scan ultrasonography, and fundus photography were assessed on day 1, weeks 1, 2, and 4 and months 2 and 3. RESULTS: There were 19 eyes of 18 consecutive patients with mean follow-up after IVT injection of 28 weeks. Of the 19 eyes, 17 eyes (89%) experienced clearing of vitreous hemorrhage within 1 to 5 weeks (mean, 1.7 weeks) with visible triamcinolone precipitates along with blood clot in the inferior aspect of fundus. Of these 17 eyes, 12 eyes (63%) maintained vitreous hemorrhage-free condition at last follow-up with a mean visual acuity of 20/63 (range, 20/320 20/25), whereas 5 (29%) developed recurrent vitreous hemorrhage after clearing of vitreous hemorrhage. Vitreous hemorrhage was not cleared in 2 eyes, which required surgical procedures. CONCLUSIONS: IVT injection may be beneficial for clearing recurrent postvitrectomy Diabetic Vitreous Hemorrhage.
Adult
;
Aged
;
Diabetic Retinopathy/*complications/diagnosis
;
Female
;
Follow-Up Studies
;
Glucocorticoids/*administration & dosage
;
Humans
;
Injections
;
Male
;
Microscopy, Acoustic
;
Middle Aged
;
Postoperative Hemorrhage/diagnosis/*drug therapy/etiology
;
Retrospective Studies
;
Time Factors
;
Treatment Outcome
;
Triamcinolone Acetonide/*administration & dosage
;
Visual Acuity
;
Vitrectomy/*adverse effects
;
Vitreous Body
;
Vitreous Hemorrhage/diagnosis/*drug therapy/etiology
2.Intravitreal Bevacizumab Alone versus Combined with Macular Photocoagulation in Diabetic Macular Edema.
Soo Jeong LEE ; Ei Tae KIM ; Yeon Sung MOON
Korean Journal of Ophthalmology 2011;25(5):299-304
PURPOSE: To compare the efficacy between intravitreal bevacizumab and combination treatment (bevacizumab and macular photocoagulation) for the treatment of diabetic macular edema (DME). In addtion, changes of DME type were researched using optical coherence tomography. METHODS: The present study included 90 eyes with bevacizumab injection and 38 eyes with combination treatment. Using chart records, patients were reviewed until 6 months after treatment. The present study compared changes of visual acuity (VA) and macular thickness at each follow up. DME was classified into 4 types and the morphologic pattern was compared. RESULTS: In patients with the bevacizumab injection only, VA improved from 0.29 +/- 0.18 to 0.48 +/- 0.26 at 1 month and returned to 0.32 +/- 0.20 at 6 months after treatment. In the combination treatment, VA improved from 0.32 +/- 0.22 to 0.52 +/- 0.26 at 1 month and returned to 0.36 +/- 0.18 at 6 months after treatment. There was no significant improvement of VA at the final follow-up with either treatment. There was significant decrease of macular thickness except in the mixed DME type. CONCLUSIONS: The combination treatment did not yield better VA or macular thickness reduction at 6 months than bevacizumab injection alone. By classifying and observing the change of DME type, determining the treatment objectively and predicting the effectiveness of treatment can be helpful.
Angiogenesis Inhibitors/administration & dosage
;
Antibodies, Monoclonal, Humanized/*administration & dosage
;
Diabetic Retinopathy/*complications/diagnosis/therapy
;
Dose-Response Relationship, Drug
;
Female
;
Fluorescein Angiography
;
Follow-Up Studies
;
Fundus Oculi
;
Humans
;
Intravitreal Injections
;
Laser Coagulation/*methods
;
Macular Edema/diagnosis/etiology/*therapy
;
Male
;
Microscopy, Acoustic
;
Middle Aged
;
Retrospective Studies
;
Tomography, Optical Coherence
;
Treatment Outcome
;
Vascular Endothelial Growth Factor A/antagonists & inhibitors
;
Visual Acuity
3.Intravitreal Bevacizumab Alone versus Combined with Macular Photocoagulation in Diabetic Macular Edema.
Soo Jeong LEE ; Ei Tae KIM ; Yeon Sung MOON
Korean Journal of Ophthalmology 2011;25(5):299-304
PURPOSE: To compare the efficacy between intravitreal bevacizumab and combination treatment (bevacizumab and macular photocoagulation) for the treatment of diabetic macular edema (DME). In addtion, changes of DME type were researched using optical coherence tomography. METHODS: The present study included 90 eyes with bevacizumab injection and 38 eyes with combination treatment. Using chart records, patients were reviewed until 6 months after treatment. The present study compared changes of visual acuity (VA) and macular thickness at each follow up. DME was classified into 4 types and the morphologic pattern was compared. RESULTS: In patients with the bevacizumab injection only, VA improved from 0.29 +/- 0.18 to 0.48 +/- 0.26 at 1 month and returned to 0.32 +/- 0.20 at 6 months after treatment. In the combination treatment, VA improved from 0.32 +/- 0.22 to 0.52 +/- 0.26 at 1 month and returned to 0.36 +/- 0.18 at 6 months after treatment. There was no significant improvement of VA at the final follow-up with either treatment. There was significant decrease of macular thickness except in the mixed DME type. CONCLUSIONS: The combination treatment did not yield better VA or macular thickness reduction at 6 months than bevacizumab injection alone. By classifying and observing the change of DME type, determining the treatment objectively and predicting the effectiveness of treatment can be helpful.
Angiogenesis Inhibitors/administration & dosage
;
Antibodies, Monoclonal, Humanized/*administration & dosage
;
Diabetic Retinopathy/*complications/diagnosis/therapy
;
Dose-Response Relationship, Drug
;
Female
;
Fluorescein Angiography
;
Follow-Up Studies
;
Fundus Oculi
;
Humans
;
Intravitreal Injections
;
Laser Coagulation/*methods
;
Macular Edema/diagnosis/etiology/*therapy
;
Male
;
Microscopy, Acoustic
;
Middle Aged
;
Retrospective Studies
;
Tomography, Optical Coherence
;
Treatment Outcome
;
Vascular Endothelial Growth Factor A/antagonists & inhibitors
;
Visual Acuity
4.Dose Dependent Effects of Intravitreal Triamcinolone Acetonide on Diffuse Diabetic Macular Edema.
Joon Sung BAE ; Sung Joon PARK ; I Rum HAM ; Tae Gon LEE
Korean Journal of Ophthalmology 2009;23(2):80-85
PURPOSE: To evaluate the effect of different doses of intravitreal triamcinolone acetonide on diffuse diabetic macular edema. METHODS: In a retrospective study, 44 eyes with diffuse diabetic macular edema were treated with an intravitreal injection of 4 mg (n=12 eyes), 8 mg (n=17) or 25 mg (n=15) of triamcinolone acetonide (TA). Optical coherence tomography, best-corrected logMAR visual acuity and Goldmann tonometry were performed at baseline, 1 week, and 1, 3, 6, 9 and 12 months after treatment. Mean follow-up was 9.8 months (standard deviation=2.3) with a range of 5-12 months. RESULTS: The duration of intravitreal TA effects on macular thickness and visual acuity increased with increasing dosage. An observed increase in intraocular pressure induced by TA was not significantly associated with dosage. CONCLUSIONS: In patients with diffuse diabetic macular edema who receive intravitreal TA, effects may last longer after a dosage of 25 mg, than after lower doses of 8 mg or 4 mg.
Adult
;
Aged
;
Aged, 80 and over
;
Diabetic Retinopathy/*complications/drug therapy/pathology
;
Dose-Response Relationship, Drug
;
Female
;
Follow-Up Studies
;
Glucocorticoids/*administration & dosage
;
Humans
;
Injections
;
Intraocular Pressure
;
Macular Edema/diagnosis/*drug therapy/etiology
;
Male
;
Middle Aged
;
Retrospective Studies
;
Time Factors
;
Tomography, Optical Coherence
;
Treatment Outcome
;
Triamcinolone Acetonide/*administration & dosage
;
Visual Acuity
;
Vitreous Body